SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Anil Kachroo, Michael A. Schwarzschild, Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson׳s disease, Brain Research, 2014, 1563, 103

    CrossRef

  2. 2
    Xiaolan Lu, Xiaoxia Li, Yi Zhao, Zheng Zheng, Shaochen Guan, Piu Chan, Contemporary epidemiology of gout and hyperuricemia in community elderly in Beijing, International Journal of Rheumatic Diseases, 2014, 17, 4
  3. 3
    D.Q. Li, J. Zhao, S.P. Li, High-performance liquid chromatography coupled with post-column dual-bioactivity assay for simultaneous screening of xanthine oxidase inhibitors and free radical scavengers from complex mixture, Journal of Chromatography A, 2014, 1345, 50

    CrossRef

  4. 4
    R. Fleischmann, B. Kerr, L.-T. Yeh, M. Suster, Z. Shen, E. Polvent, V. Hingorani, B. Quart, K. Manhard, J. N. Miner, S. Baumgartner, Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia, Rheumatology, 2014,

    CrossRef

  5. 5
    Li-Min Liu, Shu-Fen Cheng, Po-Chuen Shieh, Jang-Chang Lee, Jih-Jung Chen, Chi-Tang Ho, Sheng-Chu Kuo, Daih-Huang Kuo, Li-Jiau Huang, Tzong-Der Way, The methanol extract of Euonymus laxiflorus, Rubia lanceolata and Gardenia jasminoides inhibits xanthine oxidase and reduce serum uric acid level in rats, Food and Chemical Toxicology, 2014, 70, 179

    CrossRef

  6. 6
    D.A. Jankowska, A. Trautwein-Schult, A. Cordes, P. Hoferichter, C. Klein, R. Bode, K. Baronian, G. Kunze, Arxula adeninivorans xanthine oxidoreductase and its application in the production of food with low purine content, Journal of Applied Microbiology, 2013, 115, 3
  7. 7
    Samuel Joshua Pragasam, MahaboobKhan Rasool, Dietary component p-coumaric acid suppresses monosodium urate crystal-induced inflammation in rats, Inflammation Research, 2013, 62, 5, 489

    CrossRef

  8. 8
    Huan Wang, Yong Wei, Xianglei Kong, Dongmei Xu, Effects of Urate-Lowering Therapy in Hyperuricemia on Slowing the Progression of Renal Function: A Meta-Analysis, Journal of Renal Nutrition, 2013, 23, 5, 389

    CrossRef

  9. 9
    S Liu, C Yin, N Chu, L Han, C Li, IL-8 –251T/A and IL-12B 1188A/C polymorphisms are associated with gout in a Chinese male population, Scandinavian Journal of Rheumatology, 2013, 42, 2, 150

    CrossRef

  10. 10
    Jiunn-Horng Chen, Wen-Harn Pan, Chih-Cheng Hsu, Wen-Ting Yeh, Shao-Yuan Chuang, Pin-Yu Chen, Hui-Chen Chen, Chwen-Tzuei Chang, Wei-Lun Huang, Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: A prospective study, Arthritis Care & Research, 2013, 65, 1
  11. 11
    A. L. Ariev, N. A. Kunitskaya, L. S. Kozina, New data on gout and hyperuricemia: Incidence rates, risk factors and aging-associated manifestations, Advances in Gerontology, 2013, 3, 2, 138

    CrossRef

  12. 12
    G. Zandman-Goddard, H. Amital, N. Shamrayevsky, R. Raz, V. Shalev, G. Chodick, Rates of adherence and persistence with allopurinol therapy among gout patients in Israel, Rheumatology, 2013, 52, 6, 1126

    CrossRef

  13. 13
    Robert A Terkeltaub, H Ralph Schumacher, John D Carter, Herbert SB Baraf, Robert R Evans, Jian Wang, Shirletta King-Davis, Steven P Weinstein, Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator, Arthritis Research & Therapy, 2013, 15, 1, R25

    CrossRef

  14. 14
    Cássia R. Silva, Janaina K. Fröhlich, Sara M. Oliveira, Thaíssa N. Cabreira, Mateus F. Rossato, Gabriela Trevisan, Amanda L. Froeder, Guilherme V. Bochi, Rafael N. Moresco, Margareth L. Athayde, Juliano Ferreira, The antinociceptive and anti-inflammatory effects of the crude extract of Jatropha isabellei in a rat gout model, Journal of Ethnopharmacology, 2013, 145, 1, 205

    CrossRef

  15. 15
    Yong Gil Hwang, Kenneth G Saag, Gout, 2013,

    CrossRef

  16. 16
    Dong Wook Jung, Young Hye Cho, Sang Yeoup Lee, Evaluation, Co-morbidity and Management of Obesity in the Elderly, The Korean Journal of Obesity, 2012, 21, 2, 77

    CrossRef

  17. 17
    Tamer A. Gheita, Hussein S. El-Fishawy, Mohamed M. Nasrallah, Hani Hussein, Insulin resistance and metabolic syndrome in primary gout: relation to punched-out erosions, International Journal of Rheumatic Diseases, 2012, 15, 6
  18. 18
    Shiguo Liu, Kun Zhang, Congcong Yin, Lin Han, Yuping Sun, Wei Ren, Nan Chu, Changgui Li, Polymorphisms −1082 G/A and −819 C/T in the Interleukin-10 Gene Are Not Associated with Gout Susceptibility in the Chinese Han Male Population, Genetic Testing and Molecular Biomarkers, 2012, 16, 8, 879

    CrossRef

  19. 19
    Giulia Malaguarnera, Maria Giordano, Mariano Malaguarnera, Rasburicase for the treatment of tumor lysis in hematological malignancies, Expert Review of Hematology, 2012, 5, 1, 27

    CrossRef

  20. 20
    H. Ralph Schumacher, Robert R. Evans, Kenneth G. Saag, James Clower, William Jennings, Steven P. Weinstein, George D. Yancopoulos, Jian Wang, Robert Terkeltaub, Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid–lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study, Arthritis Care & Research, 2012, 64, 10
  21. 21
    H. Ralph Schumacher, John S. Sundy, Robert Terkeltaub, Howard R. Knapp, Scott J. Mellis, Neil Stahl, George D. Yancopoulos, Yuhwen Soo, Shirletta King-Davis, Steven P. Weinstein, Allen R. Radin, Rilonacept (Interleukin-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, 2012, 64, 3
  22. 22
    Clare M. Perrin, Jennifer A. Swift, Step kinetics on monosodium urate monohydrate single crystal surfaces: an in situ AFM study, CrystEngComm, 2012, 14, 5, 1709

    CrossRef

  23. 23
    Hyon K. Choi, Gout & Other Crystal Arthropathies, 2012,

    CrossRef

  24. 24
    Naomi Schlesinger, Difficult-to-Treat Gouty Arthritis, Drugs, 2011, 71, 11, 1413

    CrossRef

  25. 25
    Thomas Bardin, Pascal Richette, Épidémiologie et génétique de la goutte, La Presse Médicale, 2011, 40, 9, 830

    CrossRef

  26. 26
    Kshamata Skeete, Erik P. Hess, Tod Clark, Steven Moran, Sanjeev Kakar, Marco Rizzo, Epidemiology of Suspected Wrist Joint Infection Versus Inflammation, The Journal of Hand Surgery, 2011, 36, 3, 469

    CrossRef

  27. 27
    Gérard Reach, L’observance dans la goutte, Revue du Rhumatisme, 2011, 78, 4, 319

    CrossRef

  28. 28
    Shu-Jung Wang, Hung-Pin Tu, Albert Min-Shan Ko, Shang-Lun Chiang, Shean-Jaw Chiou, Su-Shin Lee, Yi-Shan Tsai, Chi-Pin Lee, Ying-Chin Ko, Lymphocyte α-kinase is a gout-susceptible gene involved in monosodium urate monohydrate-induced inflammatory responses, Journal of Molecular Medicine, 2011, 89, 12, 1241

    CrossRef

  29. 29
    T. S. Han, A. Tajar, M. E. J. Lean, Obesity and weight management in the elderly, British Medical Bulletin, 2011, 97, 1, 169

    CrossRef

  30. 30
    Yanyan Zhu, Bhavik J. Pandya, Hyon K. Choi, Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008, Arthritis & Rheumatism, 2011, 63, 10
  31. 31
    Gérard Reach, Treatment adherence in patients with gout, Joint Bone Spine, 2011, 78, 5, 456

    CrossRef

  32. 32
    KJM Jansen Dirken-Heukensfeldt, TAM Teunissen, EH van de Lisdonk, ALM Lagro-Janssen, “Clinical features of women with gout arthritis.” A systematic review, Clinical Rheumatology, 2010, 29, 6, 575

    CrossRef

  33. 33
    Hyon K Choi, A prescription for lifestyle change in patients with hyperuricemia and gout, Current Opinion in Rheumatology, 2010, 22, 2, 165

    CrossRef

  34. 34
    Pascal Richette, Thomas Bardin, Gout, The Lancet, 2010, 375, 9711, 318

    CrossRef

  35. 35
    John D. Beck, John H. Deegan, John T. Riehl, Joel C. Klena, Incidence of Scapholunate Ligament Dissociation in Patients With Aspiration-Confirmed Gout, The Journal of Hand Surgery, 2010, 35, 12, 1938

    CrossRef

  36. 36
    Jae-Bum Jun, Young-In Na, Hyun-Jin Kim, Shin-Hee Kim, Yoo-Sin Park, Juseop Kang, Measurement of Purine Contents in Korean Alcoholic Beverages, The Journal of the Korean Rheumatism Association, 2010, 17, 4, 368

    CrossRef

  37. 37
    Michael E. Zychowicz, Richard S. Pope, Elke Graser, The current state of care in gout: Addressing the need for better understanding of an ancient disease, Journal of the American Academy of Nurse Practitioners, 2010, 22,
  38. 38
    Robert Terkeltaub, Update on gout: new therapeutic strategies and options, Nature Reviews Rheumatology, 2010, 6, 1, 30

    CrossRef

  39. 39
    Bruce D. Adams, Douglas W. Lowery, Rosen's Emergency Medicine – Concepts and Clinical Practice, 2010,

    CrossRef

  40. 40
    George M. Brenner, Craig W. Stevens, Pharmacology, 2010,

    CrossRef

  41. 41
    Jeannie Chao, Robert Terkeltaub, A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout, Current Rheumatology Reports, 2009, 11, 2, 135

    CrossRef

  42. 42
    Monika Reuss-Borst, Differentialdiagnostik und Therapie der Gicht, Medizinische Klinik, 2009, 104, 9, 710

    CrossRef

  43. 43
    Robert Terkeltaub, Clinical trials report, Current Rheumatology Reports, 2008, 10, 3, 215

    CrossRef

  44. 44
    Mary De Vera, M. Mushfiqur Rahman, James Rankin, Jacek Kopec, Xiang Gao, Hyon Choi, Gout and the risk of parkinson's disease: A cohort study, Arthritis Care & Research, 2008, 59, 11
  45. 45
    Gabriela Hernández-Molina, Antonio Cachafeiro-Vilar, Antonio R. Villa, Josefina Alberú, Marina Rull-Gabayet, Gout in Renal Allograft Recipients According to the Pretransplant Hyperuricemic Status, Transplantation, 2008, 86, 11, 1543

    CrossRef

  46. 46
    Ben Yu-Jih Su, Han-Ming Lai, Chung-Jen Chen, Ying-Chou Chen, Chun-Kai Chiu, Ko-Ming Lin, Shan-Fu Yu, Tien-Tsai Cheng, Ischemia heart disease and greater waist circumference are risk factors of renal function deterioration in male gout patients, Clinical Rheumatology, 2008, 27, 5, 581

    CrossRef

  47. 47
    Angelo L. Gaffo, Kenneth G. Saag, Management of Hyperuricemia and Gout in CKD, American Journal of Kidney Diseases, 2008, 52, 5, 994

    CrossRef

  48. 48
    Merry R. Sherman, Mark G.P. Saifer, Fernando Perez-Ruiz, PEG-uricase in the management of treatment-resistant gout and hyperuricemia, Advanced Drug Delivery Reviews, 2008, 60, 1, 59

    CrossRef

  49. 49
    S. J. Lee, J. D. Hirsch, R. Terkeltaub, D. Khanna, J. A. Singh, A. Sarkin, A. Kavanaugh, Perceptions of disease and health-related quality of life among patients with gout, Rheumatology, 2008, 48, 5, 582

    CrossRef

  50. 50
    Won Cheoul Jang, Yun-Hyoung Nam, Su-Min Park, Young-Chang Ahn, Sung-Hoon Park, Jung-Yoon Choe, Im-Hee Shin, Seong-Kyu Kim, T6092C polymorphism of SLC22A12 gene is associated with serum uric acid concentrations in Korean male subjects, Clinica Chimica Acta, 2008, 398, 1-2, 140

    CrossRef

  51. 51
    Hein JEM Janssens, Matthijs Janssen, Eloy H van de Lisdonk, Piet LCM van Riel, Chris van Weel, Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial, The Lancet, 2008, 371, 9627, 1854

    CrossRef

  52. 52
    Christopher M. Wise, Crystal-Associated Arthritis in the Elderly, Rheumatic Disease Clinics of North America, 2007, 33, 1, 33

    CrossRef

  53. 53
    Naohiko Anzai, Hitoshi Endou, Drug discovery for hyperuricemia, Expert Opinion on Drug Discovery, 2007, 2, 9, 1251

    CrossRef

  54. 54
    Thomas Bardin, Épidémiologie de la goutte, Revue du Rhumatisme, 2007, 74, 2, 147

    CrossRef

  55. 55
    Shi-Fu Mo, Feng Zhou, Yao-Zhong Lv, Qing-Hua Hu, Dong-Mei Zhang, Ling-Dong Kong, Hypouricemic Action of Selected Flavonoids in Mice: Structure–Activity Relationships, Biological & Pharmaceutical Bulletin, 2007, 30, 8, 1551

    CrossRef

  56. 56
    Suzanne Novak, Arthur K. Melkonian, Pankaj A. Patel, Nathan L. Kleinman, Nancy Joseph-Ridge, Richard A. Brook, Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use*, Current Medical Research and Opinion, 2007, 23, 3, 623

    CrossRef

  57. 57
    S. Unger, A.-K. Tausche, S. Kopprasch, S.R. Bornstein, M. Aringer, J. Gräßler, Molekulare Grundlagen der primär-renalen Hyperurikämie, Zeitschrift für Rheumatologie, 2007, 66, 7, 556

    CrossRef

  58. 58
    Jasvinder A. Singh, James S. Hodges, John P. Toscano, Steven M. Asch, Quality of care for gout in the US needs improvement, Arthritis Care & Research, 2007, 57, 5
  59. 59
    Marie Hudson, Elham Rahme, Hugues Richard, Louise Pilote, Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: A class effect?, Arthritis Care & Research, 2007, 57, 3
  60. 60
    Nathan L. Kleinman, Richard A. Brook, Pankaj A. Patel, Arthur K. Melkonian, Truman J. Brizee, James E. Smeeding, Nancy Joseph-Ridge, The Impact of Gout on Work Absence and Productivity, Value in Health, 2007, 10, 4
  61. 61
    I Pande, An update on gout, Indian Journal of Rheumatology, 2006, 1, 2, 60

    CrossRef

  62. 62
    Nancy Joseph-Ridge, Susan Cazzetta, Patricia MacDonald, Clinical Trials in Crystal Arthropathy, Rheumatic Disease Clinics of North America, 2006, 32, 2, 359

    CrossRef

  63. 63
    Susan J. Lee, Robert A. Terkeltaub, Does diet contribute to the development of hyperuricemia?, Current Rheumatology Reports, 2006, 8, 3, 207

    CrossRef

  64. 64
    George Nuki, Gout, Medicine, 2006, 34, 10, 417

    CrossRef

  65. 65
    Lan X. Chen, H. Ralph Schumacher, Gout: can we create an evidence-based systematic approach to diagnosis and management?, Best Practice & Research Clinical Rheumatology, 2006, 20, 4, 673

    CrossRef

  66. 66
    Robert Terkeltaub, Hyperuricemia treatment: is creatinine clearance a safer allopurinol dosing meter than plasma creatinine levels?, Nature Clinical Practice Rheumatology, 2006, 2, 2, 68

    CrossRef

  67. 67
    A. K. Tausche, S. Unger, K. Richter, C. Wunderlich, J. Grässler, B. Roch, H. E. Schröder, Hyperurikämie und Gicht, Der Internist, 2006, 47, 5, 509

    CrossRef

  68. 68
    Susan J. Lee, Robert A. Terkeltaub, New developments in clinically relevant mechanisms and treatment of hyperuricemia, Current Rheumatology Reports, 2006, 8, 3, 224

    CrossRef

  69. 69
    Gim Gee Teng, Raj Nair, Kenneth G Saag, Pathophysiology, Clinical Presentation and Treatment of Gout, Drugs, 2006, 66, 12, 1547

    CrossRef

  70. 70
    J. D. Moolenburgh, M. K. Reinders, T. L. Th. A. Jansen, Rasburicase treatment in severe tophaceous gout: a novel therapeutic option, Clinical Rheumatology, 2006, 25, 5, 749

    CrossRef

  71. 71
    Susan J Lee, Robert A Terkeltaub, Arthur Kavanaugh, Recent developments in diet and gout, Current Opinion in Rheumatology, 2006, 18, 2, 193

    CrossRef

  72. 72
    Pascal Richette, Thomas Bardin, Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol, Nature Clinical Practice Rheumatology, 2006, 2, 6, 338

    CrossRef

  73. 73
    Richard A. Brook, Nathan L. Kleinman, Pankaj A. Patel, Arthur K. Melkonian, Truman J. Brizee, James E. Smeeding, Nancy Joseph-Ridge, The economic burden of gout on an employed population, Current Medical Research and Opinion, 2006, 22, 7, 1381

    CrossRef

  74. 74
    Stefan K Drexler, Sandra M Sacre, Brian M Foxwell, Toll-like receptors: a new target in rheumatoid arthritis?, Expert Review of Clinical Immunology, 2006, 2, 4, 585

    CrossRef

  75. 75
    N Edwards, Crystal-Induced Arthropathies, 2006,

    CrossRef

  76. 76
    Peter Simkin, Crystal-Induced Arthropathies, 2006,

    CrossRef

  77. 77
    Kenneth Saag, Ted Mikuls, Joel Abbott, Crystal-Induced Arthropathies, 2006,

    CrossRef

  78. 78
    Christopher M. Wise, Crystal-Associated Arthritis in the Elderly, Clinics in Geriatric Medicine, 2005, 21, 3, 491

    CrossRef

  79. 79
    Larry W. Moreland, Febuxostat — Treatment for Hyperuricemia and Gout?, New England Journal of Medicine, 2005, 353, 23, 2505

    CrossRef

  80. 80
    Ru Liu-Bryan, Peter Scott, Anya Sydlaske, David M. Rose, Robert Terkeltaub, Innate immunity conferred by toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal–induced inflammation, Arthritis & Rheumatism, 2005, 52, 9
  81. 81
    Kenneth G. Saag, Ted R. Mikuls, Recent advances in the epidemiology of gout, Current Rheumatology Reports, 2005, 7, 3, 235

    CrossRef

  82. 82
    Christopher W. Wu, Robert Terkeltaub, What do epidemiologic studies tell us about hyperuricemia and cardiovascular disease and death?, Current Rheumatology Reports, 2005, 7, 3, 211

    CrossRef

  83. 83
    Amy Anderson, Jasvinder A Singh, Pegloticase for chronic gout, The Cochrane Library,
  84. 84
    Hein J Janssens, Peter LBJ Lucassen, Floris A Van de Laar, Matthijs Janssen, Eloy H Van de Lisdonk, Systemic corticosteroids for acute gout, The Cochrane Library,
  85. 85
    HJ Janssens, PLBJ Lucassen, FA Laar, M Janssen, EH Lisdonk, Systemic steroids for acute gout, The Cochrane Library,